Merck Serono, the biopharmaceutical division of Merck, has introduced its updated electronic injection RebiSmart for self-administration of Rebif (interferon beta-1a). Rebif is the disease-modifying treatment of the company, which is used as basic therapy for the treatment of relapsing-remitting form of multiple sclerosis (MS).
The new RebiSmart allows patients to inject Rebif themselves, and may also collect information about injection times, dates and doses administered and store and wirelessly send the safe MSdialog server. But only the new RebiSmart must be inserted into a corresponding transmitter and then a button to be pressed.... Read More - http://www.ms-uk.org/rebif
- Similar Topics
- Last post